Breaking News Instant updates and real-time market news.

VBLT

VBL Therapeutics

07:02
11/29/16
11/29
07:02
11/29/16
07:02

VBL Therapeutics announces OS data for VB-111 Phase 2 study

VBL Therapeutics announced top-line results from its exploratory Phase 2 study of VB-111 in patients with advanced, differentiated thyroid cancer. As previously announced, this trial met its primary endpoint, which was defined as 25% progression-free survival at 6 months, in heavily-pretreated patients with late-stage disease. A dose-dependent response was seen, with 35% of patients reaching PFS-6 in the therapeutic dose cohort, versus 25% in a low-dose cohort. Given this positive clinical response, the Company continued to follow patients for overall survival, or OS, data, which was not a primary endpoint. Although the trial included a small number of patients and was not powered to show OS differences, the new data show a dose-response and evidence of an overall survival benefit in the cohort of patients treated with multiple therapeutic doses of VB-111, compared to patients who received a single low dose of VB-111. Only one patient remained alive in the low-dose cohort, compared to a tail of about 50% in the high dose group.

  • 29

    Nov

VBLT VBL Therapeutics

06/06/16
CHDN
06/06/16
NO CHANGE
CHDN
VBL Therapeutics data provides enhanced visibility, says Chardan
Chardan noted that VBL announced that in a Phase II trial involving glioblastoma multiforme patients, VBL's VB-111 drug followed by VB-111 with Avastin led to a statistically significant increase in median overall survival, or OS, of 59 weeks compared to 32 weeks of OS in patients who received VB-111 followed by Avastin only. The firm says that the data reduces the uncertainty of the Phase III trial of VB-111 and "further reinforces the unprecedented nature" of VB-111's Phase II data. The firm keeps a $20 price target and Buy rating on the shares.
06/06/16
ROTH
06/06/16
NO CHANGE
Target $22
ROTH
Buy
VBL Therapeutics' ASCO presentations underscore potential, says Roth Capital
Roth Capital analyst Joseph Pantginis said VBL Therapeutics' two poster presentations on VB-111 at ASCO underscore the platform's potential in various cancers. Most notably, maturing data from an ongoing trial in ovarian cancer showed an "impressive" dose-response relationship, said Pantginis, who keeps a Buy rating and $22 price target on VBL shares.
06/07/16
CHDN
06/07/16
NO CHANGE
Target $20
CHDN
Buy
Chardan continues to see significant upside for VBL Therapeutics
Chardan continues to see significant upside for VBL Therapeutics shares given VB-111 has convincing efficacy signals for rGBM, ovarian, and thyroid cancer types, an immune-therapeutic effect for VB-111 has been supported in the rGBM and ovarian trials, and the product has orphan drug designations in the US and Euripe for rGBM, Fast Track designation by the FDA for rGBM, and a special protocol assessment by the FDA for the Phase III program in rGBM. Chardan rates VBL Therapeutics a Buy with a $20 price target on shares.
06/28/16
HCWC
06/28/16
INITIATION
Target $11
HCWC
Buy
VBL Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started VBL Therapeutics with a Buy rating and $11 price target.

TODAY'S FREE FLY STORIES

NLNK

NewLink Genetics

$18.59

0.51 (2.82%)

, MRK

Merck

$62.55

0.405 (0.65%)

14:32
04/25/17
04/25
14:32
04/25/17
14:32
Hot Stocks
NewLink drops after panel questions Ebola vaccine efficacy »

Shares of NewLink…

NLNK

NewLink Genetics

$18.59

0.51 (2.82%)

MRK

Merck

$62.55

0.405 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 10

    May

  • 12

    May

  • 27

    May

  • 31

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

X

U.S. Steel

$31.19

-0.01 (-0.03%)

14:31
04/25/17
04/25
14:31
04/25/17
14:31
Options
US Steel sees a large spread trade ahead of earnings »

US Steel sees a large…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

14:25
04/25/17
04/25
14:25
04/25/17
14:25
Conference/Events
Leerink healthcare analysts hold an analyst/industry conference call »

Healthcare Analysts…

WRI

Weingarten Realty

$33.75

-0.64 (-1.86%)

14:23
04/25/17
04/25
14:23
04/25/17
14:23
Recommendations
Weingarten Realty analyst commentary  »

Weingarten Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

DIS

Disney

$115.29

1.59 (1.40%)

14:19
04/25/17
04/25
14:19
04/25/17
14:19
Periodicals
Disney targets Star Wars, Frozen sequels for 2019, Deadline reports »

Disney has unveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
04/25/17
04/25
14:17
04/25/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
04/25/17
04/25
14:16
04/25/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBB

Hubbell

$117.83

-3.7 (-3.04%)

14:14
04/25/17
04/25
14:14
04/25/17
14:14
Hot Stocks
Hubbell acquires connected home products maker iDevices »

iDevices announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 09

    May

  • 09

    May

  • 09

    May

TWTR

Twitter

$14.80

0.085 (0.58%)

14:13
04/25/17
04/25
14:13
04/25/17
14:13
Technical Analysis
Twitter technical comments before earnings »

Ahead of earnings news,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CL

Colgate-Palmolive

$74.15

0.49 (0.67%)

14:11
04/25/17
04/25
14:11
04/25/17
14:11
Options
Colgate attracts a call writer ahead of earnings »

Colgate attracts a call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

SQ

Square

$18.11

0.26 (1.46%)

14:06
04/25/17
04/25
14:06
04/25/17
14:06
Options
Square call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 16

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

14:05
04/25/17
04/25
14:05
04/25/17
14:05
General news
NY Fed's overnight reverse repo totaled $117.0 B, with 45 counterparties »

NY Fed's overnight…

STX

Seagate

$49.42

1.16 (2.40%)

, WDC

Western Digital

$85.77

2.66 (3.20%)

14:00
04/25/17
04/25
14:00
04/25/17
14:00
Earnings
On The Fly: What to watch in data storage earnings reports »

Companies in the data…

STX

Seagate

$49.42

1.16 (2.40%)

WDC

Western Digital

$85.77

2.66 (3.20%)

MU

Micron

$26.57

-0.75 (-2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 31

    May

  • 07

    Jun

  • 08

    Jun

14:00
04/25/17
04/25
14:00
04/25/17
14:00
General news
Stocks drifting at session highs in afternoon trading »

Stocks have been sharply…

MTBC

Medical Transcription Billing

$0.42

-0.03 (-6.67%)

13:57
04/25/17
04/25
13:57
04/25/17
13:57
Hot Stocks
Medical Transcription Billing partners with Health Compliance Network »

MTBC announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$8.89

0.18 (2.07%)

13:54
04/25/17
04/25
13:54
04/25/17
13:54
Hot Stocks
Sprint promotion adds free fifth line to unlimited offer »

Sprint announced that for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

CMA

Comerica

$70.14

0.03 (0.04%)

13:53
04/25/17
04/25
13:53
04/25/17
13:53
Hot Stocks
Comerica raises quarterly dividend 13% to 26c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WFC

Wells Fargo

$54.57

0.92 (1.71%)

13:51
04/25/17
04/25
13:51
04/25/17
13:51
Hot Stocks
Wells Fargo chairman: Stockholders sent board 'clear message of dissatisfaction' »

Commenting on the results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

D

Dominion

$77.54

-0.53 (-0.68%)

13:51
04/25/17
04/25
13:51
04/25/17
13:51
Options
Downside put buyers in Dominion Resources ahead of earnings »

Downside put buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 10

    May

  • 21

    May

WFC

Wells Fargo

$54.59

0.935 (1.74%)

13:50
04/25/17
04/25
13:50
04/25/17
13:50
Hot Stocks
Wells Fargo confirms all directors reelected, says votes dip as low as 53% »

Wells Fargo announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 31

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

PG

Procter & Gamble

$89.97

0.415 (0.46%)

13:48
04/25/17
04/25
13:48
04/25/17
13:48
Technical Analysis
Procter & Gamble technical comments before earnings »

Ahead of earnings news,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

XLNX

Xilinx

$60.65

2.96 (5.13%)

13:46
04/25/17
04/25
13:46
04/25/17
13:46
Options
Xilinx call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVHY

Vivendi

$20.34

1.39 (7.34%)

13:45
04/25/17
04/25
13:45
04/25/17
13:45
Periodicals
Vivendi's UMG valued at $22B by banks seeking float, Reuters says »

Bankers aiming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTHIY

Hitachi

$53.93

0.09 (0.17%)

, KKR

KKR

$17.51

0.25 (1.45%)

13:45
04/25/17
04/25
13:45
04/25/17
13:45
Periodicals
Hitachi plans to sell chipmaking device unit to KKR, JIP, Nikkei reports »

Hitachi (HTHIY) is…

HTHIY

Hitachi

$53.93

0.09 (0.17%)

KKR

KKR

$17.51

0.25 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

CLRO

ClearOne

$10.00

0.1 (1.01%)

13:43
04/25/17
04/25
13:43
04/25/17
13:43
Hot Stocks
ClearOne says awarded patent on 'beamforming' echo cancellation »

ClearOne announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.